FDA Seeks Boost in Drug Company Fees
14th Nov 2006, 20:47 GMT
Fees paid by Merck, Pfizer and other drug companies should be increased to help pay a larger part of the FDA's drug safety budget, according to a senior agency official.
FDA Seeks Boost in Drug Company Fees related news:
- FDA Urges Caution on Flu Drug — WSJ.com: What's News US
- FDA Suggests New Tamiflu Warning — WSJ.com: What's News US
- FDA Expands Use of Abbott's Humira — Government/ Industry Regulation News from StratCenter.com
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- FDA Decision on Novartis Drug Is Delayed — WSJ.com: What's News Europe
- Alexion gets fast-track FDA review for drug Soliris — bizjournals.com Health Care:Pharmaceuticals headlines
- FDA Orders Caution Over the use of Tamiflu — NPR Topics: Nation
- Drug Safety Reform and Risk Management Plans - A Test Case? Senior FDA Policymakers and Experts to Answer Urgent Questions at Windhover's FDA/CMS Summit Dec 4-5, Washington, DC — RedOrbit News - Health
- CombinatoRx reports revenue boost — bizjournals.com Health Care:Pharmaceuticals headlines
- Dendreon Asks FDA to OK Prostate Drug — Government/ Industry Regulation News from StratCenter.com
Latest news from Financial News News from StratCenter.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris